|Title||Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Warren B, Lee AK, Ballantyne CM, Hoogeveen RC, Pankow JS, Grams ME, Köttgen A|
|Secondary Authors||Selvin E|
|Journal||J Appl Lab Med|
|Date Published||2020 Nov 01|
BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is a novel biomarker of glycemic control proposed to monitor recent hyperglycemic excursions in persons with diabetes. The clinical utility of 1,5-AG outside of diagnosed diabetes is unclear, but it may identify people at high risk for diabetes and its complications. We compared associations of 1,5-AG with 2-h glucose for risk of major clinical complications.
RESEARCH DESIGN AND METHODS: We prospectively followed 6644 Atherosclerosis Risk in Communities (ARIC) Study participants without diagnosed diabetes for incident diagnosed diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality for ∼20 years. We assessed associations of 1,5-AG and 2-h glucose (modeled categorically and continuously with restricted cubic splines) with adverse outcomes using Cox models and evaluated improvement in risk discrimination using Harrell's c-statistic.
CONCLUSIONS: In this community-based population without diagnosed diabetes, low 1,5-AG was modestly associated with major clinical outcomes and did not outperform 2-h glucose.
|Alternate Journal||J Appl Lab Med|
|PubMed Central ID||PMC7648735|
|Grant List||K24 DK106414 / DK / NIDDK NIH HHS / United States |
R01 DK089174 / DK / NIDDK NIH HHS / United States